Wednesday, March 26, 2014 11:04:18 PM
~ ENTB = Immuno-Therapeutic Cancer Vaccine for Canines (Dog Cancer Vaccine)
The first area of focus involves the development of an immuno-therapeutic cancer vaccine for canines. One in every four dogs will develop some sort of cancer during its lifetime. The Company's goal in this area is to create a treatment that will jumpstart the dog's own immune system to fight cancer, and we have a device that is in development that we believe will be a "game-changer" for canine oncology. With the rollout of our "canines first" approach, Entest feels it can penetrate the veterinary market in the very near term (one to three years) and eventually take this immuno-therapeutic cancer vaccine into human trials once enough paid animal cases support our vaccine's efficacy.
The first area of focus involves the development of an immuno-therapeutic cancer vaccine for canines. One in every four dogs will develop some sort of cancer during its lifetime. The Company's goal in this area is to create a treatment that will jumpstart the dog's own immune system to fight cancer, and we have a device that is in development that we believe will be a "game-changer" for canine oncology. With the rollout of our "canines first" approach, Entest feels it can penetrate the veterinary market in the very near term (one to three years) and eventually take this immuno-therapeutic cancer vaccine into human trials once enough paid animal cases support our vaccine's efficacy.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
